Answers are grounded in this paper and cite their sources.
Results from the completed Cohorts 1-4 in Part 1 of the Brainshuttle™ AD study suggest that early and pronounced effects on several key markers of AD pathophysiology can be achieved with trontinemab treatment with very limited incidence of ARIA.
No takes yet. Share an insight, caveat, or question.
Kulic et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: